Tirzepatide
Also known as Mounjaro, Zepbound
Tirzepatide is a dual GIP and GLP-1 receptor agonist — the first of its kind. Clinical trials show up to 22% body weight loss (superior to semaglutide), making it the most effective weight loss medication ever approved by the FDA.
How it works
Dual agonist of GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. GIP agonism adds metabolic effects beyond GLP-1 alone, including potential adipocyte lipid metabolism modulation. Results in superior weight loss vs GLP-1 monotherapy.
Benefits
- 22%+ body weight loss in clinical trials — best in class
- Better tolerated than semaglutide for many patients
- Dramatically reduces appetite and food noise
- Superior glycemic control vs semaglutide
- Improves insulin sensitivity
- Cardiovascular benefits
- Potential muscle-preserving effects vs GLP-1 alone
Dosing
2.5–15 mg · Once weekly
Start 2.5mg/week for 4 weeks. Titrate by 2.5mg every 4 weeks to target dose (5–15mg/week).
Ranges reflect commonly cited research protocols, not a prescription. Dose with a licensed provider.
Common stacks
Reported side effects
- Nausea (less than semaglutide for many)
- GI discomfort
- Constipation
- Rare: pancreatitis
- Muscle loss without exercise
Who it’s for
Adults with obesity or overweight with comorbidities. Preferred over semaglutide for those wanting maximum weight loss effect. Medical supervision required.
Track Tirzepatide in Helix
Dose reminders, reconstitution math, vial tracking, and AI guidance — free on iOS.
Download free